Business
Rafarma Pharmaceuticals (OTC:RAFA), Announces a $1.2 Million Private Placement
Rafarma Pharmaceuticals (OTC:RAFA), Announces a $1.2 Million Private Placement.
About this update from Rafarma Pharmaceuticals, Inc. (wy)
[{"type":"text","content":"MOSCOW /PRNewswire/ --\nRafarma Pharmaceuticals (OTC:RAFA), Announces a $1.2 Million Private Placement. A $1.2 million private placement has\nbeen closed with a share price of $0.65 per share. Proceeds from this private placement are\nbeing applied to company expansion and to reduce commercial debt. Stated CEO Dave Anderson: ?As\nRafarma continues to develop new manufacturing partners, we anticipate that\nthis private placement is just the beginning of a vibrant private financing\nmarket for the pharmaceutical sector. We are pleased with the investor\nenthusiasm for Rafarma?s potential.?The\nsecurities offered in the private placement have not been registered under the\nSecurities Act of 1933, as amended (the \"Securities Act\"), or\napplicable state securities laws. Accordingly, the securities may not be\noffered or sold in the United States except pursuant to an effective registration\nstatement or an applicable exemption from the registration requirements of the\nSecurities Act and such applicable state securities laws. The securities were\noffered only to accredited investors.About Rafarma Pharmaceuticals, Inc. Operating from a new 270,000\nsquare-foot state-of-the-art manufacturing and distribution facility in Russia,\nRafarma Pharmaceuticals produces generic antibiotics and specialty\npharmaceuticals in addition to its own line of proprietary products that are\napproved by the Ministry of Health of Russian Federation. For the last three\nyears, the Russian Government has been highly focused on bolstering the\ndevelopment of the nation's domestic pharmaceutical industry. Rafarma\nPharmaceuticals' mission is to work with the auspices of aggressive federal\ninitiatives to fast-track the modernization of Russia's pharmaceutical\nindustry.For\nmore information on Rafarma Pharmaceuticals, visit: http://rafarma.comSafe Harbor StatementMatters discussed in this press\nrelease contain forward-looking statements within the meaning of the Private\nSecurities Litigation Reform Act of 1995. When used in this press release, the\nwords \"anticipate,\" \"believe,\" \"estimate,\" \"may,\"\n\"intend,\" \"expect\" and similar expressions identify such\nforward-looking statements. Actual results, performance or achievements could\ndiffer materially from those contemplated, expressed or implied by the\nforward-looking statements co...